Teacher Retirement System of Texas purchased a new position in Endologix, Inc. (NASDAQ:ELGX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 26,894 shares of the medical instruments supplier’s stock, valued at approximately $144,000.
Several other large investors also recently modified their holdings of ELGX. The Manufacturers Life Insurance Company boosted its holdings in shares of Endologix by 4.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 66,890 shares of the medical instruments supplier’s stock worth $325,000 after buying an additional 2,738 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Endologix by 211.2% during the third quarter. JPMorgan Chase & Co. now owns 109,380 shares of the medical instruments supplier’s stock valued at $488,000 after purchasing an additional 74,227 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in Endologix by 5.0% during the third quarter. Schwab Charles Investment Management Inc. now owns 337,238 shares of the medical instruments supplier’s stock valued at $1,505,000 after purchasing an additional 15,929 shares during the last quarter. Valeo Financial Advisors LLC purchased a new stake in Endologix during the third quarter valued at about $163,000. Finally, GW&K Investment Management LLC lifted its holdings in Endologix by 38.2% during the fourth quarter. GW&K Investment Management LLC now owns 218,106 shares of the medical instruments supplier’s stock valued at $1,167,000 after purchasing an additional 60,247 shares during the last quarter.
Several research firms have commented on ELGX. BidaskClub raised shares of Endologix from a “sell” rating to a “hold” rating in a report on Saturday, February 10th. Zacks Investment Research raised shares of Endologix from a “sell” rating to a “hold” rating in a report on Monday, March 19th. Piper Jaffray reaffirmed an “overweight” rating on shares of Endologix in a report on Tuesday, December 12th. ValuEngine downgraded shares of Endologix from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Finally, Oppenheimer set a $5.00 price objective on shares of Endologix and gave the company a “hold” rating in a report on Thursday, February 22nd. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $5.41.
Endologix (NASDAQ:ELGX) last announced its quarterly earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.13. Endologix had a negative return on equity of 44.91% and a negative net margin of 36.65%. The firm had revenue of $44.00 million for the quarter, compared to analysts’ expectations of $44.91 million. During the same period in the prior year, the business posted ($0.30) earnings per share. The company’s revenue was down 7.3% on a year-over-year basis. equities analysts expect that Endologix, Inc. will post -0.73 earnings per share for the current fiscal year.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.